BioXcel Therapeutics, Inc.
BTAINasdaq
$0.89
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↓ -54.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$20.9M
Enterprise Value
$104.0M
P/E
—
P/S
30.8
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-274.3%
Dividend Yield
—
Revenue (TTM)
$680,000.00
Net Income (TTM)
-$75.3M
Free Cash Flow (TTM)
-$57.4M
Gross Margin
—
Operating Margin
-7439.0%
Net Margin
-11078.5%
ROE
71.4%
ROIC
—
Debt / Equity
-1.0
Net Cash
-$83.1M
Return 1Y
-54.3%
Company profile
BioXcel Therapeutics, Inc. uses artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
- CEO
- Vimal D. Mehta
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 90
- Headquarters
- Connecticut
- Website
- bioxceltherapeutics.com
Management & directors
- Mehta VimalCEO and President
- Rodriguez JavierSee Remarks
- Steinhart Richard IChief Financial Officer
- Yocca FrankChief Scientific Officer
Roles derived from SEC Form 4 filings.
Earnings
BTAI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$206,000.00↑ +22.6%
Diluted EPS-$0.54↓ -64.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $375,000.00 | $1.4M | $2.3M | $642,000.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$82.3M | -$106.9M | -$159.6M | -$171.8M | -$67.2M | -$50.5M |
| Net income | -$82.2M | -$106.9M | -$165.8M | -$179.1M | -$59.6M | -$69.9M |
| Diluted EPS | -$3.79 | -$4.05 | -$5.92 | -$98.33 | -$23.51 | -$5.73 |
| Operating cash flow | -$66.3M | -$82.2M | -$135.3M | -$155.0M | -$72.0M | -$57.6M |
| Free cash flow | -$66.7M | -$82.6M | -$135.5M | -$155.0M | -$72.0M | -$57.6M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -42572.0% | -12448.0% | -2967.6% | -7860.0% |
| Net margin | — | — | -44201.9% | -12974.9% | -2630.1% | -10887.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $214,000.00 | $366,000.00 | $168,000.00 | $120,000.00 | $98,000.00 | $256,000.00 | $206,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$17.3M | -$15.3M | -$10.5M | -$10.1M | -$15.9M | -$14.2M | -$10.3M | -$10.2M |
| Net income | -$8.3M | -$13.7M | -$10.9M | -$7.3M | -$19.2M | -$30.9M | -$12.5M | -$12.7M |
| Diluted EPS | -$3.30 | -$5.15 | -$1.17 | -$1.50 | -$2.45 | -$2.18 | $0.40 | -$0.54 |
| Operating cash flow | -$23.2M | -$16.3M | -$14.8M | -$12.0M | -$12.6M | -$18.8M | -$14.2M | -$11.8M |
| Free cash flow | — | -$16.3M | — | -$12.0M | -$12.6M | -$18.8M | -$14.2M | -$11.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -1566.7% | -7146.3% | -2866.9% | -6011.3% | -13210.0% | -14518.4% | -4016.4% | -4962.6% |
| Net margin | -751.7% | -6378.5% | -2966.9% | -4317.9% | -15989.2% | -31541.8% | -4900.4% | -6160.7% |
Company news
May 15, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Steinhart Richard I· Chief Financial Officer | Option exercise | 35 | — | — | filing |
| 2026-06-15 | Rodriguez Javier· See Remarks | Option exercise | 35 | — | — | filing |
| 2026-06-15 | Mehta Vimal· CEO and President | Option exercise | 219 | — | — | filing |
| 2026-06-15 | Yocca Frank· Chief Scientific Officer | Option exercise | 35 | — | — | filing |
| 2026-05-20 | Mehta Vimal· CEO and President | Sale | 19,419 | $1.09 | $21,108.45 | filing |
| 2026-05-20 | Steinhart Richard I· Chief Financial Officer | Sale | 6,845 | $1.09 | $7,426.83 | filing |
| 2026-05-20 | Yocca Frank· Chief Scientific Officer | Sale | 6,845 | $1.09 | $7,426.83 | filing |
| 2026-05-20 | Rodriguez Javier· See Remarks | Sale | 6,560 | $1.08 | $7,111.04 | filing |
| 2026-05-04 | Yocca Frank· Chief Scientific Officer | Option exercise | 17,500 | — | — | filing |
| 2026-05-04 | Rodriguez Javier· See Remarks | Option exercise | 17,500 | — | — | filing |
| 2026-05-04 | Steinhart Richard I· Chief Financial Officer | Option exercise | 17,500 | — | — | filing |
| 2026-05-04 | Mehta Vimal· CEO and President | Option exercise | 49,758 | — | — | filing |
| 2026-05-01 | Yocca Frank· Chief Scientific Officer | Option exercise | 9,000 | — | — | filing |
| 2026-05-01 | Mehta Vimal· CEO and President | Option exercise | 18,000 | — | — | filing |
| 2026-05-01 | Steinhart Richard I· Chief Financial Officer | Option exercise | 9,000 | — | — | filing |
| 2026-05-01 | Rodriguez Javier· See Remarks | Option exercise | 9,000 | — | — | filing |
| 2026-03-15 | Mehta Vimal· CEO and President | Option exercise | 219 | — | — | filing |
| 2026-03-15 | Steinhart Richard I· Chief Financial Officer | Option exercise | 35 | — | — | filing |
| 2026-03-15 | Rodriguez Javier· See Remarks | Option exercise | 35 | — | — | filing |
| 2026-03-15 | Yocca Frank· Chief Scientific Officer | Option exercise | 35 | — | — | filing |
| 2026-03-14 | Mehta Vimal· CEO and President | Option exercise | 164 | — | — | filing |
| 2026-03-14 | Steinhart Richard I· Chief Financial Officer | Option exercise | 33 | — | — | filing |
| 2026-03-14 | Rodriguez Javier· See Remarks | Option exercise | 33 | — | — | filing |
| 2026-03-14 | Yocca Frank· Chief Scientific Officer | Option exercise | 33 | — | — | filing |
| 2025-12-15 | Mehta Vimal· CEO and President | Option exercise | 219 | — | — | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.